Prosecution Insights
Prosecution Insights
58 pending office actions • 36 clients • 54 examiners • 25 art units • 0 of 58 (0%) have an AI response strategy ready • 72 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 23 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 23 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 19 (33%) |
| §102 only | 7 (12%) |
| §112 only | 11 (19%) |
| Double-patenting only | 12 (21%) |
| Double-patenting + other | 2 (3%) |
| No statute on record | 7 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOWALTER, ALEXANDER KEITH | 3 | 54.9% | +50.7% |
| CHANDRAKUMAR, NIZAL S | 2 | 72.6% | +18.3% |
| SEAMAN, D MARGARET M | 2 | 76.6% | +8.0% |
| RAHMANI, NILOOFAR | 1 | 77.5% | -3.1% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.7% |
| YU, HONG | 1 | 31.2% | +5.7% |
| MARTIN, PAUL C | 1 | 41.8% | +21.7% |
| YOUNG, MICAH PAUL | 1 | 55.1% | +29.9% |
| KUCKLA, ANNA GRACE | 1 | 50.0% | +53.3% |
| ABUZEINEH, HANAN ISAM | 1 | 56.8% | +50.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18299657 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | CHANDRAKUMAR, NIZAL S | 71d overdue |
| 18007018 | NOVEL USES | SHOWALTER, ALEXANDER KEITH | 60d overdue |
| 18066883 | METHODS OF TREATMENT WITH S1P RECEPTOR MODULATORS | SHOWALTER, ALEXANDER KEITH | 60d overdue |
| 18043959 | NOVEL SALTS, CRYSTALS, AND CO-CRYSTALS | SHOWALTER, ALEXANDER KEITH | 37d overdue |
| 18867252 | IMPROVED SYNTHETIC METHODS FOR MAKING LACTONES | CHANDRAKUMAR, NIZAL S | 18d overdue |
| 19374186 | NOVEL PI3K AND/OR PIKK INHIBITORS, ANTIBODY-DRUG CONJUGATES COMPRISING THE SAME AND USES THEREOF | HUYNH, PHUONG N | — |
| 19203107 | PARTICLE SEPARATOR SYSTEM, MATERIALS, AND METHODS OF USE | MARTIN, PAUL C | — |
| 19194059 | ORAL POLYPEPTIDE COMPOSITION | YOUNG, MICAH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1629 | 4 |
| 1623 | 4 |
| 1641 | 3 |
| 1614 | 3 |
| 1618 | 3 |
| 1625 | 3 |
| 1628 | 3 |
| 1624 | 3 |
| 1658 | 3 |
| 1621 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19433491 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | Fujian Haixi Pharmaceuticals Co., Ltd. | RAHMANI, NILOOFAR | 1691 | §102 | Non-Final OA | — | Pending | Dec 26, 2025 |
| 19374186 | NOVEL PI3K AND/OR PIKK INHIBITORS, ANTIBODY-DRUG CONJUGATES COMPRISING THE SAME AND USES THEREOF | Hutchmed Limited | HUYNH, PHUONG N | 1641 | §112 | Non-Final OA | — | Pending | Oct 30, 2025 |
| 19274087 | O/W-EMULSIONS COMPRISING SEMIFLUORINATED ALKANES | Novaliq GmbH | YU, HONG | 1614 | DP | Non-Final OA | — | Pending | Jul 18, 2025 |
| 19203107 | PARTICLE SEPARATOR SYSTEM, MATERIALS, AND METHODS OF USE | Levitasbio, Inc. | MARTIN, PAUL C | 1653 | §102 | Non-Final OA | — | Pending | May 08, 2025 |
| 19194059 | ORAL POLYPEPTIDE COMPOSITION | Shenzhen Oralead Pharma Co., Ltd. | YOUNG, MICAH PAUL | 1618 | §103 | Final Rejection | — | Pending | Apr 30, 2025 |
| 18867252 | IMPROVED SYNTHETIC METHODS FOR MAKING LACTONES | P2 Science, Inc. | CHANDRAKUMAR, NIZAL S | 1625 | §112 | Non-Final OA | 18d overdue | Pending | Nov 19, 2024 |
| 18843308 | MODULATORS OF ACKR3 AND USES THEREOF | Stichting VU | SEAMAN, D MARGARET M | §112 | Non-Final OA | — | Pending | Sep 03, 2024 | |
| 18800808 | FARNESOID X RECEPTOR MODULATORS | Intercept Pharmaceuticals, Inc. | KUCKLA, ANNA GRACE | DP | Non-Final OA | — | Pending | Aug 12, 2024 | |
| 18729669 | PROMOTER FOR THE EXPRESSION OF GENES IN PARTICULAR CUX1-POSITIVE CELLS IN LAYER 2/3 OF MOUSE CORTEX | Friedrich Miescher Institute For Biomedical Research | ABUZEINEH, HANAN ISAM | §112 | Non-Final OA | — | Pending | Jul 17, 2024 | |
| 18741740 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | Intra-Cellular Therapies, Inc. | O DELL, DAVID K | 1621 | DP | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18692494 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING HYDROXYMELONAL FORMATE ESTER | P2 Science, Inc. | WALKER, AJA ARYANNA | §112 | Non-Final OA | — | Pending | Mar 15, 2024 | |
| 18546831 | COMPOSITION FOR SKIN REGENERATION, WHITENING, ANTIOXIDATION, OR WOUND TREATMENT, COMPRISING STEM CELL-DERIVED EXOSOME AS ACTIVE INGREDIENT, AND USE THEREOF | Ehlbio Co., Ltd. | CLARK, AMY LYNN | 1628 | DP | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18596349 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | STEVENS, MARK V | 1613 | Other | Non-Final OA | 14d | Pending | Mar 05, 2024 |
| 18580492 | CONJUGATE OF CELL-PENETRATING PEPTIDE AND MELPHALAN, AND PREPARATION CONTAINING CONJUGATE | Alephoson Biopharmaceuticals Limited | COFFA, SERGIO | §103 | Non-Final OA | — | Pending | Jan 18, 2024 | |
| 18567743 | NOVEL SALTS AND CRYSTALS | Intra-Cellular Therapies, Inc. | RODRIGUEZ, RAYNA B | 1628 | §103 | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18564378 | PHARMACEUTICAL COMPOSITION FOR TREATING BRAIN DISEASES COMPRISING ANTIBODY SPECIFICALLY BINDING TO ASM PROTEIN AS ACTIVE INGREDIENT | Kyungpook National University Industry-Academic Cooperation Foundation | STEPHENS, AMELIA CAROLE | 1645 | DP | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18504472 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | Montelino Therapeutics, Inc. | COLEMAN, BRENDA LIBBY | 1624 | §112 | Non-Final OA | 27d | Pending | Nov 08, 2023 |
| 18555198 | SAFE HARBOR LOCI FOR CELL ENGINEERING | Hangzhou Qihan Biotech Co., Ltd. | CORDAS, EMILY ANN | 1632 | §102 | Non-Final OA | 83d | Pending | Oct 12, 2023 |
| 18377756 | STABILISED PROTEIN COMPOSITIONS BASED ON SEMIFLUORINATED ALKANES | Novaliq GmbH | KOSACK, JOSEPH R | 3991 | Other | Non-Final OA | 27d | Pending | Oct 06, 2023 |
| 18481168 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | RODRIGUEZ-GARCIA, VALERIE | 1600 | DP | Final Rejection | — | Pending | Oct 04, 2023 |
| 18550883 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd. | WHITE, DAWANNA SHAR-DAY | 1627 | DPOther | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18550111 | DETECTION OF BIOMARKERS USEFUL IN DIAGNOSING CHRONIC ENTEROPATHIES IN CATS | Vetica Labs, Inc. | ROONEY, NORA MAUREEN | 1641 | §103 | Non-Final OA | — | Pending | Sep 11, 2023 |
| 18450240 | ORAL CARE PRODUCTS AND METHODS | BASF Corporation | ROBERTS, LEZAH | 1612 | §103 | Non-Final OA | 86d overdue | Pending | Aug 15, 2023 |
| 18263318 | CRYSTALLINE FORM OF A PIPERAZINYL-THIAZOLE DERIVATIVE | Idorsia Pharmaceuticals Ltd. | ROMERO, KRISTEN WANG | 1624 | Other | Non-Final OA | 87d overdue | Pending | Jul 27, 2023 |
| 18263302 | SALT CRYSTALS | Intra-Cellular Therapies, Inc. | MOORE, SUSANNA | 1624 | DP | Final Rejection | — | Pending | Jul 27, 2023 |
| 18261446 | CHOCOLATE COMPOSITION AND METHOD FOR OBTAINING THE SAME | Barry Callebaut AG | MERRIAM, ANDREW E | 1791 | §103 | Final Rejection | — | Pending | Jul 13, 2023 |
| 18256817 | HDAC6 BINDING PROTEINS AND THEIR ANTI-VIRAL USE | UNIVERSITY OF ZURICH | TAYLOR, LIA ELAN | 1641 | §112 | Non-Final OA | 55d | Pending | Jun 09, 2023 |
| 18266096 | NOVEL METHODS | The Trustees of the University of Pennsylvania | REDWOOD, CHRISTOPHER EVAN | 1629 | §103 | Non-Final OA | — | Pending | Jun 08, 2023 |
| 18320173 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | CHONG, YONG SOO | 1623 | DP | Final Rejection | — | Pending | May 18, 2023 |
| 18308288 | INHIBITORS OF ENPP1 AND MODULATION OF BONE GROWTH | Petragen, Inc. | SEAMAN, D MARGARET M | 1625 | §102 | Final Rejection | 5d overdue | Pending | Apr 27, 2023 |
| 18304987 | USE OF FOLIC ACID AND FOLATE MODIFICATION IN INDUCING B-CELL IMMUNE TOLERANCE AND TARGETING mIgM-POSITIVELY-EXPRESSED B-CELL LYMPHOMA | Fudan University | MEJIAS, SAMANTHA LEE | 1618 | §103 | Non-Final OA | 88d overdue | Pending | Apr 21, 2023 |
| 18299657 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | Tme Therapeutics LLC | CHANDRAKUMAR, NIZAL S | 1625 | §112 | Final Rejection | 71d overdue | Pending | Apr 12, 2023 |
| 18029518 | Prebiotic Oral Care Compositions and Methods | UNIVERSITEIT GENT | LIU, TRACY | 1614 | §103 | Final Rejection | 15d | Pending | Mar 30, 2023 |
| 18043959 | NOVEL SALTS, CRYSTALS, AND CO-CRYSTALS | Intra-Cellular Therapies, Inc. | SHOWALTER, ALEXANDER KEITH | 1629 | §103 | Final Rejection | 37d overdue | Pending | Mar 03, 2023 |
| 18042103 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. | FETTEROLF, BRANDON J | 1626 | §103 | Non-Final OA | 3d overdue | Pending | Feb 17, 2023 |
| 18040618 | PHARMACEUTICAL COMPOSITION OF AQUAPORIN INHIBITOR AND PREPARATION METHOD THEREOF | Aeromics, Inc. | ARNOLD, ERNST V | 1613 | DP | Non-Final OA | — | Pending | Feb 03, 2023 |
| 18007018 | NOVEL USES | Intra-Cellular Therapies, Inc. | SHOWALTER, ALEXANDER KEITH | 1629 | §103 | Non-Final OA | 60d overdue | Pending | Jan 26, 2023 |
| 18156749 | SEMIFLUORINATED ALKANE COMPOSITIONS | Novaliq GmbH | HOWELL, THEODORE R | 1628 | Other | Non-Final OA | 14d | Pending | Jan 19, 2023 |
| 18152110 | SYSTEMS AND METHODS FOR WRITING, READING, AND CONTROLLING DATA STORED IN A POLYMER | Iridia, Inc. | WOOLWINE, SAMUEL C | 1681 | §102 | Final Rejection | — | Pending | Jan 09, 2023 |
| 18066883 | METHODS OF TREATMENT WITH S1P RECEPTOR MODULATORS | Priothera Limited | SHOWALTER, ALEXANDER KEITH | 1629 | Other | Non-Final OA | 60d overdue | Pending | Dec 15, 2022 |
| 18001764 | NOVEL ISOMERIC COMPOUNDS COMPRISING A RING-OPENED THIOSUCCINIMIDE GROUP, AN OLIGOPEPTIDE FRAGMENT AND A CHIRAL MOIETY | Genequantum Healthcare (Suzhou) Co., Ltd. | NGUYEN, TAM M | 1771 | §103 | Non-Final OA | 25d overdue | Pending | Dec 14, 2022 |
| 17928381 | STABLE PEPTIDES HAVING RENALASE AGONIST ACTIVITY | Yale University | KATAKAM, SUDHAKAR | 1658 | §112 | Non-Final OA | — | Pending | Nov 29, 2022 |
| 18057650 | SYSTEMS AND METHODS FOR WRITING, READING, AND CONTROLLING DATA STORED IN A POLYMER | Iridia, Inc. | BASHAR, MOHAMMED A | 1681 | DP | Non-Final OA | — | Pending | Nov 21, 2022 |
| 17996499 | MEDICAL USE OF DARIDOREXANT | Idorsia Pharmaceuticals Ltd. | WARD, PAUL V | 1622 | §112 | Non-Final OA | — | Pending | Oct 18, 2022 |
| 17917337 | USE OF BROMODOMAIN INHIBITORS FOR TREATMENT OF HUNTINGTON'S DISEASE | Rumi Scientific Holdings, Inc. | SIMMONS, CHRIS E | 1622 | §103 | Final Rejection | 15d | Pending | Oct 06, 2022 |
| 17995220 | THE USE OF DIFFUSION ENHANCING COMPOUNDS FOR TREATMENT OF VIRAL AND BACTERIAL INDUCED RESPIRATORY DISEASE | Diffusion Pharmaceuticals LLC | THOMAS, TIMOTHY P | 1614 | §103 | Non-Final OA | 45d overdue | Pending | Sep 30, 2022 |
| 17758540 | RSPO1 PROTEINS AND THEIR USE | UNIVERSITE COTE D'AZUR | REYNOLDS, FRED H | 1658 | DP | Non-Final OA | — | Pending | Jul 08, 2022 |
| 17758352 | COMPOSITIONS HAVING THIOREDOXIN ACTIVITY AND RELATED METHODS | Orpro Therapeutics, Inc. | KOMATSU, LI N | 1658 | Other | Non-Final OA | — | Pending | Jul 01, 2022 |
| 17757572 | NOVEL USES | Intra-Cellular Therapies, Inc. | HSU, GRACE CHING | 1627 | §112 | Non-Final OA | 28d | Pending | Jun 17, 2022 |
| 17673480 | Prebiotic Oral Care Compositions and Methods | UNIVERSITEIT GENT | PETRITSCH, AMANDA MICHELLE | 1612 | §103 | Final Rejection | — | Pending | Feb 16, 2022 |
| 17597903 | METHODS FOR TREATING TUMORS | Nh Theraguix | PERREIRA, MELISSA JEAN | 1618 | DPOther | Non-Final OA | — | Pending | Jan 28, 2022 |
| 17579559 | PARTICLE SEPARATOR SYSTEM, MATERIALS, AND METHODS OF USE | Levitasbio, Inc. | SPANGLER, JOSEPH RANKIN | 1656 | §102 | Non-Final OA | 22d | Pending | Jan 19, 2022 |
| 17568298 | COMPOSITIONS AND METHODS FOR REPELLING AND KILLING TICKS AND DETACHMENT OF FEEDING TICKS | The United States Department of Health and Human Services | BAUER, NICOLA MARIA | 1621 | DP | Final Rejection | — | Pending | Jan 04, 2022 |
| 17297580 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING OMEGA-3 FATTY ACID ETHYL ESTERS | Novaliq GmbH | MCKOY, QUINCY ANDRE | 1626 | §103 | Non-Final OA | 28d | Pending | May 27, 2021 |
| 17223551 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS | Yale University | MCMILLIAN, KARA RENITA | 1623 | §102 | Non-Final OA | — | Pending | Apr 06, 2021 |
| 17279518 | NOVEL USES | Intra-Cellular Therapies, Inc. | CHENG, KAREN | 1623 | Other | Non-Final OA | — | Pending | Mar 24, 2021 |
| 17263440 | AGENT FOR INHIBITING RECURRENCE OF HEMATOLOGICAL MALIGNANCY IN PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL TRANSPLANTATION | Priothera Limited | KUCHARCZK, JED A | 1623 | §103 | Non-Final OA | — | Pending | Jan 26, 2021 |
| 15533959 | COMPOSITION, METHOD, USE AND PRODUCT | Barry Callebaut AG | KERSHAW, KELLY P | 1791 | §103 | Non-Final OA | — | Pending | Jun 07, 2017 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial